Edgestream Partners L.P. Raises Position in Moderna, Inc. (NASDAQ:MRNA)

Edgestream Partners L.P. lifted its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 270.8% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 97,961 shares of the company's stock after buying an additional 71,544 shares during the period. Edgestream Partners L.P.'s holdings in Moderna were worth $2,777,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Crowley Wealth Management Inc. bought a new stake in shares of Moderna in the 4th quarter worth approximately $41,000. Itau Unibanco Holding S.A. raised its holdings in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. Vega Investment Solutions bought a new stake in Moderna during the 4th quarter valued at $45,000. Sentry Investment Management LLC bought a new stake in Moderna during the 1st quarter valued at $31,000. Finally, Deseret Mutual Benefit Administrators increased its holdings in shares of Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ MRNA traded up $0.14 on Thursday, reaching $32.20. 6,016,987 shares of the company's stock traded hands, compared to its average volume of 8,917,052. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $126.42. The business's 50 day simple moving average is $27.77 and its two-hundred day simple moving average is $31.00.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The firm had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same quarter in the prior year, the company posted ($3.07) earnings per share. The business's revenue for the quarter was down 35.3% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a research report on Sunday. Royal Bank Of Canada cut their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Evercore ISI cut their target price on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Cowen initiated coverage on shares of Moderna in a research report on Sunday. They issued a "hold" rating for the company. Finally, William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Four research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna has an average rating of "Hold" and an average price target of $46.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.